Water extract of the fruits of Alpinia oxyphylla inhibits osteoclast differentiation and bone loss

BMC Complementary and Alternative Medicine

Jin Yeul Ma¹  Han Sung Kim²  Ji Hyung Park²  Chung-Jo Lee¹  Taesoo Kim¹  Ki-Shuk Shim¹  Hyunil Ha¹ 

[1]KM-Based Herbal Drug Development Group, Korea Institute of Oriental Medicine, Daejeon 305-811, Republic of Korea

[2]Department of Biomedical Engineering, Institute of Medical Engineering and Yonsei-Fraunhofer Medical Device Lab, Yonsei University, Wonju, Gangwon 220-710, Republic of Korea

关键词: Bone loss;    RANKL;    Alpinia oxyphylla;    Osteoclast;   

Others  :  1086584
DOI  :  10.1186/1472-6882-14-352

 received in 2014-07-01, accepted in 2014-09-19,  发布年份 2014

【 摘 要 】

Background

Excessive bone resorption by osteoclasts causes pathological bone destruction, seen in various bone diseases. There is accumulating evidence that certain herbal extracts have beneficial effects on bone metabolism. The fruits of Alpinia oxyphylla has been traditionally used for the treatment of diarrhea and enuresis. In this study, we investigated the effects of water extract of the fruits of Alpinia oxyphylla (WEAO) on osteoclast differentiation and osteoclast-mediated bone destruction.

Methods

For osteoclast differentiation assay, mouse bone marrow-derived macrophages (BMMs) were cultured in the presence of RANKL and M-CSF. RANKL signaling pathways and gene expression of transcription factors regulating osteoclast differentiation were investigated by real-time PCR and Western blotting. A constitutively active form of NFATc1 was retrovirally transduced into BMMs. Bone resorbing activity of mature osteoclast was examined on a plate coated with an inorganic crystalline calcium phosphate. The in vivo effect against bone destruction was assessed in a murine model of RANKL-induced osteoporosis by micro-computed tomography and bone metabolism marker analyses.

Results

WEAO dose-dependently inhibited RANKL-induced osteoclast differentiation from BMMs by targeting the early stages of osteoclast differentiation. WEAO inhibited RANKL-induced expression of NFATc1, the master regulator of osteoclast differentiation. Overexpression of a constitutively active form of NFATc1 blunted the inhibitory effect of WEAO on osteoclast differentiation, suggesting that NFATc1 is a critical target of the inhibitory action of WEAO. WEAO inhibited RANKL-induced expression of c-Fos, an upstream activator of NFATc1, by suppressing the classical NF-κB signaling pathway. WEAO also inhibited RANKL-induced down-regulation of Id2 and MafB, negative regulators of NFATc1. WEAO does not directly affect bone resorbing activity of mature osteoclasts. In accordance with the in vitro results, WEAO attenuated RANKL-induced bone destruction in mice by inhibiting osteoclast differentiation.

Conclusions

This study demonstrates that WEAO exhibits a protective effect against bone loss by inhibiting RANKL-induced osteoclast differentiation. These findings suggest that WEAO might be useful for the prevention and treatment of bone diseases associated with excessive bone resorption.

【 授权许可】

   
2014 Ha et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Negishi-Koga T, Takayanagi H: Ca2 + −NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev 2009, 231:241-256.
• [2]Tanaka S, Nakamura K, Takahasi N, Suda T: Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 2005, 208:30-49.
• [3]Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
• [4]Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
• [5]Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T: Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999, 190:1741-1754.
• [6]Tanaka S, Takahashi N, Udagawa N, Tamura T, Akatsu T, Stanley ER, Kurokawa T, Suda T: Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 1993, 91:257-263.
• [7]Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yoshioka K, Rao A, Yoneda T: Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 2004, 114:475-484.
• [8]Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH: Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem Biophys Res Commun 2006, 351:99-105.
• [9]Yamashita T, Yao Z, Li F, Zhang Q, Badell IR, Schwarz EM, Takeshita S, Wagner EF, Noda M, Matsuo K, Xing L, Boyce BF: NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 2007, 282:18245-18253.
• [10]Gohda J, Akiyama T, Koga T, Takayanagi H, Tanaka S, Inoue J: RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J 2005, 24:790-799.
• [11]Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, Ostrowski MC, Olsen BR, Glimcher LH: NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 2008, 118:3775-3789.
• [12]Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T: Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
• [13]Zhao B, Ivashkiv LB: Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors. Arthritis Res Ther 2011, 13:234. BioMed Central Full Text
• [14]Putnam SE, Scutt AM, Bicknell K, Priestley CM, Williamson EM: Natural products as alternative treatments for metabolic bone disorders and for maintenance of bone health. Phytother Res 2007, 21:99-112.
• [15]Banu J, Varela E, Fernandes G: Alternative therapies for the prevention and treatment of osteoporosis. Nutr Rev 2012, 70:22-40.
• [16]Commission CP: Pharmacopoeia of the People’s Republic of China (First Division). Beijing, China: China Medical Science and Technology Press; 2010:273-274.
• [17]Zhang J, Wang S, Li Y, Xu P, Chen F, Tan Y, Duan J: Anti-diarrheal constituents of Alpinia oxyphylla. Fitoterapia 2013, 89:149-156.
• [18]Wang CZ, Yuan HH, Bao XL, Lan MB: In vitro antioxidant and cytotoxic properties of ethanol extract of Alpinia oxyphylla fruits. Pharm Biol 2013, 51:1419-1425.
• [19]Shin TY, Won JH, Kim HM, Kim SH: Effect of Alpinia oxyphylla fruit extract on compound 48/80-induced anaphylactic reactions. Am J Chin Med 2001, 29:293-302.
• [20]Yamahara J, Li YH, Tamai Y: Anti-ulcer effect in rats of bitter cardamon constituents. Chem Pharm Bull (Tokyo) 1990, 38:3053-3054.
• [21]Zhang ZJ, Cheang LC, Wang MW, Li GH, Chu IK, Lin ZX, Lee SM: Ethanolic extract of fructus Alpinia oxyphylla protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebrafish. Cell Mol Neurobiol 2012, 32:27-40.
• [22]Yu X, An L, Wang Y, Zhao H, Gao C: Neuroprotective effect of Alpinia oxyphylla Miq. fruits against glutamate-induced apoptosis in cortical neurons. Toxicol Lett 2003, 144:205-212.
• [23]Ha H, An H, Shim KS, Kim T, Lee KJ, Hwang YH, Ma JY: Ethanol extract of Atractylodes macrocephala protects bone loss by inhibiting osteoclast differentiation. Molecules 2013, 18:7376-7388.
• [24]Lee JH, Kim HN, Yang D, Jung K, Kim HM, Kim HH, Ha H, Lee ZH: Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling. J Biol Chem 2009, 284:13725-13734.
• [25]Ichida F, Nishimura R, Hata K, Matsubara T, Ikeda F, Hisada K, Yatani H, Cao X, Komori T, Yamaguchi A, Yoneda T: Reciprocal roles of MSX2 in regulation of osteoblast and adipocyte differentiation. J Biol Chem 2004, 279:34015-34022.
• [26]Li YH, Chen F, Wang JF, Wang Y, Zhang JQ, Guo T: Analysis of nine compounds from Alpinia oxyphylla fruit at different harvest time using UFLC-MS/MS and an extraction method optimized by orthogonal design. Chem Cent J 2013, 7:134. BioMed Central Full Text
• [27]Tsoyi K, Jang HJ, Lee YS, Kim YM, Kim HJ, Seo HG, Lee JH, Kwak JH, Lee DU, Chang KC: (+)-Nootkatone and (+)-valencene from rhizomes of Cyperus rotundus increase survival rates in septic mice due to heme oxygenase-1 induction. J Ethnopharmacol 2011, 137:1311-1317.
• [28]Jin JH, Lee DU, Kim YS, Kim HP: Anti-allergic activity of sesquiterpenes from the rhizomes of Cyperus rotundus. Arch Pharm Res 2011, 34:223-228.
• [29]Seo EJ, Lee DU, Kwak JH, Lee SM, Kim YS, Jung YS: Antiplatelet effects of Cyperus rotundus and its component (+)-nootkatone. J Ethnopharmacol 2011, 135:48-54.
• [30]Murase T, Misawa K, Haramizu S, Minegishi Y, Hase T: Nootkatone, a characteristic constituent of grapefruit, stimulates energy metabolism and prevents diet-induced obesity by activating AMPK. Am J Physiol Endocrinol Metab 2010, 299:E266-E275.
• [31]Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, Bachler MA, Amano H, Aburatani H, Ishikawa H, Wagner EF: Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004, 279:26475-26480.
• [32]Lee J, Kim K, Kim JH, Jin HM, Choi HK, Lee SH, Kook H, Kim KK, Yokota Y, Lee SY, Choi Y, Kim N: Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood 2006, 107:2686-2693.
• [33]Kim K, Kim JH, Lee J, Jin HM, Kook H, Kim KK, Lee SY, Kim N: MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 2007, 109:3253-3259.
• [34]Oh J, Lee MS, Yeon JT, Choi SW, Kim HS, Shim H, Lee SY, Youn BS, Yokota Y, Kim JH, Kwak HB: Inhibitory regulation of osteoclast differentiation by interleukin-3 via regulation of c-Fos and Id protein expression. J Cell Physiol 2012, 227:1851-1860.
• [35]Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH: Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. Mol Pharmacol 2010, 77:17-25.
• [36]Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R: Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997, 3:1285-1289.
• [37]Tomimori Y, Mori K, Koide M, Nakamichi Y, Ninomiya T, Udagawa N, Yasuda H: Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss. J Bone Miner Res 2009, 24:1194-1205.
• [38]Naylor K, Eastell R: Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 2012, 8:379-389.